Overview of Unicycive's Legal Situation
Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is currently facing a class action lawsuit that has raised concerns among investors. The law firm Bragar Eagel & Squire, P.C., known for its focus on protecting shareholders' rights, has stepped forward to encourage those affected by the company's alleged misrepresentation of its manufacturing compliance capabilities for a new drug application.
Details of the Allegations
The lawsuit stems from claims that Unicycive misled investors about its New Drug Application (NDA) for oxylanthanum carbonate (OLC), intended for treating hyperphosphatemia in chronic kidney disease patients undergoing dialysis. The complaint alleges that the company's assurances regarding its readiness to meet regulatory compliance were significantly exaggerated.
Impact of the FDA Findings
On June 10, 2025, it was revealed that the FDA had detected significant deficiencies in the current good manufacturing practices (cGMP) at one of Unicycive's contracted manufacturing vendors. This information fundamentally altered the perception of the company’s operational readiness, resulting in a sharp decline in stock value—over 40% at the time.
Continued Stock Decline
The series of unfortunate announcements continued when, on June 30, 2025, Unicycive disclosed that the FDA had sent a Complete Response Letter regarding the OLC NDA, referencing ongoing compliance issues at the same manufacturing partner. This event further impacted the stock price, which plummeted nearly 30% to close at $4.77 per share on that date.
Next Steps for Investors
Investors who purchased Unicycive shares between March 29, 2024, and June 27, 2025, and have experienced a financial loss, are advised to consult with the firm Bragar Eagel & Squire, P.C. The deadline for investors to apply to be appointed as lead plaintiff in the class action is approaching, with a date set for October 14, 2025.
How to Participate
Anyone who may have suffered due to the discrepancy in Unicycive’s reported manufacturing capabilities is encouraged to reach out for guidance on their legal options. The firm emphasizes that there is no financial obligation to discuss potential claims.
Bragar Eagel & Squire, P.C.: Advocates for Shareholder Rights
The law firm, Bragar Eagel & Squire, P.C., boasts a strong track record of standing up for individual and institutional investors. They handle various complex litigation cases across many jurisdictions and possess substantial expertise in securities law. For those interested in learning more about their approach or the specifics of the case, detailed information can be obtained directly from their website.
Frequently Asked Questions
What is the current situation for Unicycive Therapeutics?
Unicycive is facing a class action lawsuit for allegedly misleading investors about its readiness to meet FDA manufacturing requirements.
Who should consider joining the class action?
Investors who acquired stock in Unicycive between March 29, 2024, and June 27, 2025, and suffered losses should consider joining the class action.
What led to the significant stock price drop?
Announcements regarding compliance issues revealed by the FDA significantly impacted investor confidence, leading to substantial stock price declines.
What should I do if I'm a Unicycive investor?
If you are a Unicycive investor, it is advisable to contact Bragar Eagel & Squire, P.C. to understand your rights and options.
What is the deadline for joining the lawsuit?
The deadline to apply as a lead plaintiff in the class action lawsuit is set for October 14, 2025.
